Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy

References

• Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111. doi:10.1038/nrclinonc.2017.15728994423
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102:1016–1021. doi:10.1111/j.1572-0241.2007.01104.x17324130
   PubMed Web of Science ®Google Scholar
• Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–522. doi:10.1038/nrgastro.2011.13121808282
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–1289.24681130
   PubMed Web of Science ®Google Scholar
• Jutric Z, Johnston WC, Hoen HM, et al. Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the national cancer database. HPB (Oxford). 2016;18:79–87. doi:10.1016/j.hpb.2015.07.00626776855
   PubMed Web of Science ®Google Scholar
• Weber SM, Ribero D, O’Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669–680. doi:10.1111/hpb.1244126172134
   PubMed Web of Science ®Google Scholar
• Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23:235–243. doi:10.1245/s10434-015-4642-926059651
   PubMed Web of Science ®Google Scholar
• Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143–155. doi:10.1111/liv.1408930843343
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15:527–536. doi:10.1080/17474124.2021.185352733215952
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2021;30:317–324. doi:10.1080/13543784.2021.1837774
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232. doi:10.1038/s41590-018-0044-z29379119
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39:26–42. doi:10.1055/s-0038-167680630809789
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi:10.1038/3507412211323675
   PubMed Web of Science ®Google Scholar
• Zhang GM, Xia YJ, Guo XX, et al. Reference intervals for total bilirubin, ALT, AST and creatinine in healthy Chinese elderly. Med Sci Monit. 2014;20:1778–1782. doi:10.12659/MSM.89214825272068
   PubMed Web of Science ®Google Scholar
• van Beek JH, de Moor MH, de Geus EJ, et al. The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet. 2013;43:329–339. doi:10.1007/s10519-013-9593-y23580007
   PubMed Web of Science ®Google Scholar
• Jin J, Zhu P, Liao Y, Li J, Liao W, He S. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget. 2015;6(22):19217–19227. doi:10.18632/oncotarget.426526057470
   PubMedGoogle Scholar
• Yang Z, Zhang J, Lu Y, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget. 2015;6(40):43090–43098. doi:10.18632/oncotarget.571926506519
   PubMedGoogle Scholar
• Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer. 1988;61(10):2100–2108. doi:10.1002/1097-0142(19880515)61:10<2100::AID-CNCR2820611028>3.0.CO;2-Z2834038
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957–971. doi:10.1007/BF0154265494699
   PubMedGoogle Scholar
• Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-A population-based cohort study. Int J Cancer. 2020;146:692–698. doi:10.1002/ijc.3230330924141
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261–6272. doi:10.3748/wjg.v23.i34.626128974892
   PubMed Web of Science ®Google Scholar
• Li H, Wang J, Liu H, et al. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. Aging. 2020;12:3451–3472. doi:10.18632/aging.10282132087064
   PubMedGoogle Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi:10.1038/nm.339424202395
   PubMed Web of Science ®Google Scholar
• Moses K, Brandau S. Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016;28:187–196. doi:10.1016/j.smim.2016.03.01827067179
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141:293–302. doi:10.1016/j.ygyno.2016.03.00826972336
   PubMed Web of Science ®Google Scholar
• Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366–375. doi:10.1053/gast.2002.3098311832451
   PubMed Web of Science ®Google Scholar
• Casadei GA, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2019;51:681–688. doi:10.1016/j.dld.2018.09.01630327251
   PubMedGoogle Scholar
• He C, Peng W, Li C, Wen TF. Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Medicine. 2017;96:e8540. doi:10.1097/MD.000000000000854029137062
   PubMed Web of Science ®Google Scholar
• Zhao LY, Yang DD, Ma XK, et al. The prognostic value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments. J Cancer. 2019;10:2299–2311. doi:10.7150/jca.3066331258733
   PubMed Web of Science ®Google Scholar
• Scarà S, Bottoni P, Scatena R. CA 19-9: biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:247–260.26530370
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European group on tumor markers (EGTM) status report. Ann Oncol. 2010;21:441–447. doi:10.1093/annonc/mdp33219690057
   PubMed Web of Science ®Google Scholar
• Moro A, Mehta R, Sahara K, et al. The impact of Preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27:2888–2901. doi:10.1245/s10434-020-08350-832198569
   PubMed Web of Science ®Google Scholar
• Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37:218–222. doi:10.1136/jcp.37.2.2186198342
   PubMed Web of Science ®Google Scholar
• Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:2787–2794. doi:10.1245/s10434-008-0081-118685896
   PubMed Web of Science ®Google Scholar
• Yamashita S, Passot G, Aloia TA, et al. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017;104:267–277. doi:10.1002/bjs.1041528052308
   PubMed Web of Science ®Google Scholar
• Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31:7–11. doi:10.1002/hep.51031010310613720
   PubMed Web of Science ®Google Scholar
• Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:204–207. doi:10.1111/j.1572-0241.2000.01685.x10638584
   PubMed Web of Science ®Google Scholar
• Kannagi R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struct Biol. 2002;12:599–608. doi:10.1016/S0959-440X(02)00365-212464311
   PubMed Web of Science ®Google Scholar
• Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci. 2010;1183:158–182. doi:10.1111/j.1749-6632.2009.05131.x20146714
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–266. doi:10.1038/nri205617380156
   PubMed Web of Science ®Google Scholar
• Crocker PR, Redelinghuys P. Siglecs as positive and negative regulators of the immune system. Biochem Soc Trans. 2008;36:1467–1471. doi:10.1042/BST036146719021577
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Sakuma K, Kawamura YI, et al. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and −9. J Immunol. 2012;188:4690–4700. doi:10.4049/jimmunol.110060522467657
   PubMed Web of Science ®Google Scholar
• Galli C, Basso D, Plebani M. CA 19-9: handle with care. Clin Chem Lab Med. 2013;51:1369–1383. doi:10.1515/cclm-2012-074423370912
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:79–90. doi:10.21037/hbsn.2017.01.0628503555
   PubMed Web of Science ®Google Scholar
• Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69:259–270. doi:10.1016/j.critrevonc.2008.09.00818977670
   PubMed Web of Science ®Google Scholar
• Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2018;48:703–711. doi:10.1093/jjco/hyy08229893894
   PubMed Web of Science ®Google Scholar
• Rizzo A, Tavolari S, Ricci AD, et al. Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: promises and failures. Cancers. 2020;12:3256. doi:10.3390/cancers12113256
   PubMed Web of Science ®Google Scholar